Maven Securities LTD Invests $1.61 Million in Immunome, Inc. $IMNM

Maven Securities LTD acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $1,611,000. Maven Securities LTD owned 0.07% of Immunome at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd boosted its position in shares of Immunome by 6.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after buying an additional 631 shares during the period. Creative Planning boosted its position in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares during the period. Profund Advisors LLC boosted its position in shares of Immunome by 16.5% during the third quarter. Profund Advisors LLC now owns 19,260 shares of the company’s stock worth $226,000 after buying an additional 2,723 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the period. Finally, Strs Ohio acquired a new position in shares of Immunome during the fourth quarter worth about $64,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $18.38 on Monday. The stock has a 50 day moving average price of $21.77 and a 200 day moving average price of $21.71. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The stock has a market capitalization of $2.08 billion, a PE ratio of -7.72 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on IMNM shares. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research report on Friday. Stephens reduced their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Truist Financial upped their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Craig Hallum upped their price objective on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.17.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime purchased 10,500 shares of Immunome stock in a transaction that occurred on Friday, June 5th. The stock was purchased at an average cost of $19.45 per share, with a total value of $204,225.00. Following the completion of the transaction, the director owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. This trade represents a 31.90% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Max Rosett sold 65,000 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 139,438 shares of company stock valued at $2,964,664. 7.21% of the stock is currently owned by company insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.